CTIS2022-500669-28-00进行中（未招募）1 期
Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Men and women (menopause > 5 years and FSH and LH in the postmenopausal range) aged 60-90 years with a T-score < -1 at the total hip/femoral neck, or lumbar spine (increased risk for developing osteoporosis T-score -1to -2.5, or osteoporosis T-score <-2.5)., Ability to provide informed consent
排除标准
- •DXA of hip or spine not possible e.g., due to a prosthesis, Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic., Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two days before and during the study drug dosing periods., Anti-arrhythmic medications known to cause QTc prolongation, Tyrosine kinase inhibitor therapy, Subjects with an abnormal Complete Blood Count (clinically insignificant changes would be acceptable based on the judgement of the investigators), Subjects on antiplatelet agents (Clopidogrel; Dipyridamole + ASA; ASA, Ticagrelor; Prasugrel; Ticlopidine or other) who are unable or unwilling to reduce or hold therapy prior to and during the study drug dosing periods and collection of bone biopsies. Subjects may continue their previous regimen between study drug dosing periods., Known allergy to dasatinib, quercetin, or NR, Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Presence of any condition the Investigator believes would place the subject at risk or would preclude the subject from successfully completing all aspects of the trial e.g., heart failure, malignancy etc., QTc >470 msec, T-score <-2.5 at the hip or lumbar spine. These individuals may be included if they prefer to participate or are not candidates for conventional osteoporosis therapies, Inability to take oral medication, Inability to provide fasting blood samples, Primary hyperparathyroidism, Vitamin D deficiency (<50 nM) (re-test after substitution acceptable), Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (eGFR <20) or liver function (baseline phosphatase higher than twice upper limit, rheumatism, celiac disease/malabsorption, hypogonadism, severe COPD, hypopituitarism, Cushing's disease, uncontrolled diabetes (HbA1c > 58 mmol/mol)., Antiresorptive or bone anabolic drugs for the last 3 years, Concomitant treatments known to influence bone metabolism e.g., glucocorticoids (systemic treatments), anabolic steroids, etc., Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of dasatinib+quercetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacrolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron
研究者
相似试验
招募中
1 期
Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR TrialCTIS2022-502076-23-00Odense University Hospital120
进行中（未招募）
2 期
Senolytics to Improve Osteoporosis TherapyOsteopenia, OsteoporosisNCT06018467Odense University Hospital120
招募中
不适用
Therapeutic effects of osteoporotic patients treated with Teribone in patients with hip fractureKCT0003852Gyeongsang National University Hospital104
已完成
不适用
Effects of drugs on the treatment of osteoporosis in rheumatoid arthritis patinetsosteoporosis in rheumatoid arthtitis patientsJPRN-UMIN000017945The university of Tokyo hospital39
尚未招募
不适用
Efficacy of osteoporosis treatment in the clinical outcome after arthroscopic rotator cuff repairosteoporosisJPRN-UMIN000018413Shiga University of Medical Science100